Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Sci Rep
; 7(1): 18007, 2017 12 21.
Article
in En
| MEDLINE
| ID: mdl-29269870
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Benzopyrans
/
Gene Expression Regulation
/
Lymphoma, Large B-Cell, Diffuse
/
Apoptosis
/
Proto-Oncogene Proteins c-bcl-2
/
Imino Furanoses
/
Myeloid Cell Leukemia Sequence 1 Protein
/
Antineoplastic Agents
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Sci Rep
Year:
2017
Document type:
Article
Affiliation country: